Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | P2RY10 | O00398 | 5/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21647771 | 0.80 | PPARD (0.40) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL1470873 | 0.79 | FFAR4 (0.46) | TSHR | |
| SCHEMBL21647798 | 0.78 | ADRB2 (0.39) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL29483750 | 0.78 | ADRB2 (0.39) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL21647813 | 0.76 | ADRB2 (0.40) | ADRB2ADRB1 | |
| SCHEMBL18879981 | 0.76 | TSHR (0.41) | ADRB2ADRB1TSHR | |
| SCHEMBL28599255 | 0.76 | AKR1C3 (0.40) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL28599256 | 0.76 | AKR1C3 (0.40) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL21647815 | 0.75 | P2RY10 (0.37) | ADRB2ADRB1P2RY10GPR34PPARD | |
| SCHEMBL28612879 | 0.75 | KDM4E (0.36) | ADRB2ADRB1P2RY10GPR34PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188023-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| US-12258308-B2 | Benzene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-25 | — | — | US | disclosed |
| CN-112513011-B | Benzene derivatives | 小野药品工业株式会社 | 2023-06-16 | — | — | CN | disclosed |
| US-20220089532-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-03-24 | — | — | US | disclosed |
| US-11261154-B2 | Benzene derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-03-01 | — | — | US | disclosed |
| US-20210332009-A1 | BENZENE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-10-28 | — | — | US | disclosed |
| EP-3831810-A1 | BENZENE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2021-06-09 | — | — | EP | disclosed |
| CN-112513011-A | Benzene derivatives | 小野药品工业株式会社 | 2021-03-16 | — | — | CN | disclosed |
| WO-2020027150-A1 | BENZENE DERIVATIVE | 小野薬品工業株式会社 | 2020-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12258308-B2 | Benzene derivative | PMP22, TMBIM6, MYT1 | ADRB2 832/4885ADRB1 879/4885CYP2D6 968/4885 |
| US-11261154-B2 | Benzene derivative | PMP22, TMBIM6, MYT1 | ADRB2 832/4885ADRB1 879/4885CYP2D6 968/4885 |
| US-20250188023-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | ADRB2 837/4885ADRB1 908/4885CYP2D6 959/4885 |
| US-20210332009-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | ADRB2 832/4885ADRB1 879/4885CYP2D6 968/4885 |
| US-20220089532-A1 | BENZENE DERIVATIVE | PMP22, TMBIM6, MYT1 | ADRB2 832/4885ADRB1 879/4885CYP2D6 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.